Sec Form 4 Filing - Versant Vantage I, L.P. @ Aprea Therapeutics, Inc. - 2020-05-18

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Versant Vantage I, L.P. 2. Issuer Name and Ticker or Trading Symbol Aprea Therapeutics, Inc. [ APRE] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) ONE SANSOME STREET, SUITE 3630 3. Date of Earliest Transaction (MM/DD/YY) 05/18/2020 (Street) SAN FRANCISCO, CA94104 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 05/18/2020 J( 1 ) 116,664 D $ 0 216,669 D ( 2 ) Common Stock 05/18/2020 J( 3 ) 1,750 A $ 0 1,750 I See footnotes ( 4 ) Common Stock 05/18/2020 J( 5 ) 1,750 D $ 0 0 I See footnotes ( 4 ) Common Stock 05/18/2020 J( 6 ) 1,734 A $ 0 1,734 I See footnotes ( 7 ) Common Stock 05/18/2020 J( 8 ) 1,734 D $ 0 0 I See footnotes ( 7 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Dispose d of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Versant Vantage I, L.P. ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO, CA94104 X Versant Vantage I GP, L.P. ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO, CA94104 X Versant Vantage I GP-GP, LLC ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO, CA94104 X Signatures Versant Vantage I, L.P. By: Versant Vantage I GP, L.P. Its: General Partner By: Versant Vantage I GP-GP, LLC. Its: General Partner By: /s/ Robin L. Praeger, Managing Director 05/20/2020 Signature of Reporting Person Date Versant Vantage I GP, L.P. By: Versant Vantage I GP-GP, LLC Its: General Partner By: /s/ Robin L. Praeger, Managing Director 05/20/2020 Signature of Reporting Person Date Versant Vantage I GP-GP, LLC By: /s/ Robin L. Praeger, Managing Director 05/20/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Vantage I, L.P. ("Vantage") without consideration to its partners. ( 2 )These Shares are directly held by Vantage. Versant Vantage I GP-GP, LLC ("Vantage GP-GP") is the general partner of Versant Vantage I GP, L.P. ("Vantage GP"), which is the general partner of Vantage. Each of Vantage GP-GP and Vantage GP may be deemed to indirectly beneficially own the shares beneficially owned by Vantage, but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. ( 3 )Represents a change in the form of ownership of Vantage GP by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Vantage. ( 4 )The shares are held by Vantage GP. ( 5 )Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Vantage GP without consideration to its partners. ( 6 )Represents a change in the form of ownership of Vantage GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Vantage GP. ( 7 )The shares are held by Vantage GP-GP. ( 8 )Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Vantage GP-GP without consideration to its members.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.